论文部分内容阅读
目的探讨布地奈德对急性支气管哮喘患儿血清白细胞介素17(IL-17)、白细胞介素18(IL-18)的影响及安全性。方法 100例急性支气管哮喘患儿随机分为两组,治疗组50例,对照组50例。治疗组在常规治疗的基础上加用布地奈德,对照组在常规治疗的基础上加用地塞米松,治疗前后测定血清IL-17和IL-18,并分析其不良反应。结果经比较两组在治疗后均可降低血清IL-17和IL-18的表达,并且治疗组效果优于对照组(P<0.05)。两组患者无严重不良反应的发生,总不良反应率对照组高于治疗组(P<0.05)。结论布地奈德可以明显减少急性支气管哮喘患儿IL-17和IL-18的表达,并且是安全的。
Objective To investigate the effect and safety of budesonide on serum interleukin 17 (IL-17) and interleukin 18 (IL-18) in children with acute bronchial asthma. Methods 100 cases of acute bronchial asthma were randomly divided into two groups, 50 cases in the treatment group and 50 cases in the control group. The treatment group was treated with budesonide on the basis of routine treatment, while the control group was given dexamethasone on the basis of conventional treatment. Serum IL-17 and IL-18 levels were measured before and after treatment, and their adverse reactions were analyzed. Results After treatment, the levels of IL-17 and IL-18 in serum in the two groups decreased after treatment, and the treatment group was better than the control group (P <0.05). Two groups of patients without serious adverse reactions, the total adverse reaction rate of the control group was higher than the treatment group (P <0.05). Conclusion Budesonide can significantly reduce the expression of IL-17 and IL-18 in children with acute bronchial asthma and is safe.